Takeda touts a landmark head-to-head PhIIIb win over Humira; Allergan's oral CGRP is now under FDA review
→ Takeda $TAK says their drug Entyvio has beat out AbbVie’s $ABBV Humira in a head-to-head study for ulcerative colitis. Researchers pointed to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
